LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

58.92 -1.36

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

58.83

Max

59.43

Galvenie mērījumi

By Trading Economics

Ienākumi

-43M

158M

Pārdošana

-126M

1.1B

P/E

Sektora vidējais

312.65

54.379

EPS

1.16

Peļņas marža

15.025

Darbinieki

2,617

EBITDA

-80M

257M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+25.23% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-4B

12B

Iepriekšējā atvēršanas cena

60.28

Iepriekšējā slēgšanas cena

58.92

Ziņu noskaņojums

By Acuity

50%

50%

170 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. maijs 23:48 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Dyno Nobel Returns to 1st Half Profit; Strikes Fertilizers Deals -- Update

2025. g. 11. maijs 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-China Trade Talks -- Market Talk

2025. g. 11. maijs 23:45 UTC

Tirgus saruna

Oil Rises Amid Improved Market Mood -- Market Talk

2025. g. 11. maijs 23:38 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Aristocrat Has Significant Firepower for M&A -- Market Talk

2025. g. 11. maijs 23:36 UTC

Tirgus saruna

Global Markets Uncertain About US-China Trade News -- Market Talk

2025. g. 11. maijs 23:35 UTC

Tirgus saruna

Gold Falls, Dragged by Weakening Safe-Haven Demand, Possible Profit-Taking -- Market Talk

2025. g. 11. maijs 23:33 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Dyno Nobel Returns to 1H Profit; Strikes Fertilizers Deals -- Update

2025. g. 11. maijs 23:32 UTC

Top Ziņas

Proposal Cutting Medicaid Aims for GOP Middle Ground -- WSJ

2025. g. 11. maijs 22:44 UTC

Tirgus saruna

Centaurus Metals's Jaguar Project Faces Funding Hurdles -- Market Talk

2025. g. 11. maijs 22:33 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Domain Takeover Could Create Near-Term Overhang on REA Stock -- Market Talk

2025. g. 11. maijs 20:19 UTC

Top Ziņas

Bessent Says U.S.-China Trade Talks Were 'Productive,' Without Offering Specifics -- WSJ

2025. g. 11. maijs 16:00 UTC

Top Ziņas

Trump's Budget Hawk Takes Over the DOGE Agenda. First Up: the Military -- WSJ

2025. g. 11. maijs 11:00 UTC

Top Ziņas

This Obscure New York Court Is Set to Decide Fate of Trump's Tariffs -- WSJ

2025. g. 11. maijs 08:00 UTC

Top Ziņas

China's Property Market Is a Tale of Big Cities. Everywhere Else Is Struggling. -- Barrons.com

2025. g. 11. maijs 01:00 UTC

Top Ziņas

The Spring Home Sales Season Is Shaping Up to Be a Dud -- WSJ

2025. g. 11. maijs 01:00 UTC

Top Ziņas

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia on Cease-Fire -- WSJ

2025. g. 10. maijs 21:54 UTC

Top Ziņas

GOP Tax Bill Seeks to Put Cash in Taxpayers' Pockets in Early 2026 -- Update

2025. g. 10. maijs 17:12 UTC

Top Ziņas

Europe Threatens Nord Stream 2 Sanctions to Pressure Russia to Cease Fire -- WSJ

2025. g. 10. maijs 15:41 UTC

Top Ziņas

Fed Officials Signal Pause on Adjusting Interest Rates as Trade Risks Mount -- Barrons.com

2025. g. 10. maijs 12:00 UTC

Top Ziņas

Why a Sorority Is Taking on Trump's Budget Cuts -- WSJ

2025. g. 10. maijs 09:30 UTC

Top Ziņas

The Giants of Silicon Valley Are Having a Midlife Crisis Over AI -- WSJ

2025. g. 10. maijs 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 10. maijs 03:52 UTC

Top Ziņas

China Struggles With Persistent Disinflationary Pressures as Tariffs Bite -- WSJ

2025. g. 9. maijs 23:51 UTC

Iegādes, apvienošanās, pārņemšana

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

2025. g. 9. maijs 22:06 UTC

Tirgus saruna

Arm Holdings Remains a Strong Growth Story -- Market Talk

2025. g. 9. maijs 21:37 UTC

Top Ziņas

U.S. Sets August Deadline for Debt Ceiling -- WSJ

2025. g. 9. maijs 21:10 UTC

Top Ziņas

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

2025. g. 9. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 9. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 9. maijs 20:42 UTC

Top Ziņas

Stocks Get a Break From Trade Chaos -- WSJ

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

25.23% augšup

Prognoze 12 mēnešiem

Vidējais 73.86 USD  25.23%

Augstākais 95 USD

Zemākais 52 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

6

Pirkt

11

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

170 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation